|
 |
|
|
| |
Shire gets European approval for Vpriv
 |
|
| Shire, the global specialty biopharma company based in UK, announced that the European Commission has granted marketing authorization for Vpriv (velaglucerase alfa) for the long-term treatment of type 1 Gaucher disease
|
|
 |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| GEAC permits 3 more GM crop trials
|
|
| The Genetic Engineering Appraisal Committee (GEAC) which met on July 30 in Hyderabad, has given the go ahead to agribiotech companies for the field trials of 3 more GM crops.
India
|
|
|
|
|
| |
| GEAC defers decision on phase III trials of JE vaccine
|
|
| Despite ICMR recommendations, the GEAC has decided to defer its decision on granting permission to conduct Phase III clinical trials controlled study of the safety and immununogencity of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) by M/s San |
|
|
|
|
| |
|
|
| |
| Patent pillars of biotech companies
|
|
| In the past few decades, globalization phenomenon has received considerable attention and has fashioned both the discourse and the behaviour of academics, policymakers and managers |
|
|
|
|
| More |
